Optimize MSI testing for colorectal cancer (CRC)
Rule out patients with MSS phenotypes
Testing – suitable for adults with primary colorectal cancer
Digital pathology – works with surgically resected tissue on digitized H&E slides
95% Sensitivity – equivalent when compared to standard testing techniques*
Workflow agnostic – deployment is feasible across IMS systems or shared directory
PDF report – delivered as a PDF report with user-friendly design
98% NPV – provides high confidence in MSS prediction by AI*
*Svrcek M, Saillard C, Dubois R, et al. Blind validation of MSIntuit, an AI-based pre-screening tool for MSI detection from colorectal cancer H&E slides. Poster presented at: European Society for Medical Oncology (ESMO); May 9th – 13th 2022; Paris France.
40% of CRC patients can be ruled-out from automatic IHC/PCR screening for MMR/MSI thanks to a sensitivity of 95%*
‘MSS-AI’ patients can avoid additional testing thanks to a high diagnosis precision that enables a very low rate of false negative patients.